Peptide News Digest

#Weight-Maintenance

2 stories

Clinical Trials · View digest

Lilly Orforglipron ATTAIN-MAINTAIN Phase 3b: Patients Switching Off Injectable Semaglutide or Tirzepatide to the Oral Pill Held 75-80% of Their Weight Loss Over 52 Weeks

Published May 12 in Nature Medicine and presented at ECO 2026, the first-of-its-kind ATTAIN-MAINTAIN trial (NCT06584916) tested whether adults who had already lost substantial weight on Wegovy or Zepbound could maintain it after switching to once-daily orforglipron. Over 52 weeks, the semaglutide-switch group regained an average of 1 kg and the tirzepatide-switch group an average of 5 kg, with most cardiometabolic gains preserved. Carel le Roux and Louis Aronne led the analysis.

Clinical Trials · View digest

Novo Nordisk AMAZE-12 Phase 3 Amycretin Trial Begins Recruitment May 18 — Dual GLP-1/Amylin Receptor Agonist for Weight Maintenance

Novo Nordisk's AMAZE-12 Phase 3 trial of amycretin — a dual GLP-1 and amylin receptor agonist — began recruiting on May 18, 2026. The trial evaluates amycretin specifically for weight maintenance after initial weight loss, distinguishing it from AMAZE-1 (which measures body weight change over 84 weeks). The amycretin clinical rationale rests on Phase 1 weekly subcutaneous dosing producing 22% weight reduction at 36 weeks and oral formulation producing 13.1% at 12 weeks — both reported in the Lancet earlier in 2026. Amycretin sits within Novo's next-generation pipeline alongside CagriSema (cagrilintide + semaglutide, FDA filing under review with decision expected late 2026) and the orexin-related pipeline acquired via Centessa. The amycretin program is structurally Novo's most direct response to Lilly's retatrutide.